Growth Capitalist (https://growthcapitalist.com/tag/biomed/page/32/)
Imprimis Pharmaceuticals (IMMY) announced that it has raised $4 million in a Common Stock transaction. The common stock was sold at $0.96075 per share, an approximate 1% premium to the market price ($0.95) of IMMY at deal announcement. MDB Capital Group acted as the exclusive agent on the transaction and the investor was Professional Compounding Centers of America. Issuer counsel was Morrison & Foerster, and investor counsel was G. Walter Rockwell.
AcelRx Pharmaceuticals (ACRX) announced that it has secured up to $50 million in an ATM (At the Market) transaction with MLV & Co. The purchase price is the prevailing market price at the time of the Draw Down Notice. Placement Agent counsel was LeClairRyan, PC and issuer counsel was Cooley LLP. See the PlacementTracker Deal Summary.
Achillion Pharmaceuticals (ACHN) announced that it has raised $41.8 million in a Registered Direct transaction. The common stock was sold at $6.57 per share, the market price of ACHN at deal announcement. The investors were funds managed by QVT Financial. The transaction is expected to close by 09/04/2012. See the PlacementTracker Deal Summary.
Peregrine Pharmaceuticals (PPHM) announced that it has raised $15 million in a Non-Convertible Debentures transaction. The securities accrue interest at a rate equal to the great of 8.5% and the 3-month LIBOR plus 7.5%. A series of 273,280 72-Month Warrants with an exercise price of $2.47 per share (0% premium) was issued to the investors in this transaction. The Placement Agent was not disclosed, and the investors were MidCap Financial, Oxford Finance, and Silicon Valley Bank. The Company may put up to an additional $15 million of debentures to the Investors upon satisfaction of certain conditions.
